These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 9401646

  • 1. A liquid mixed meal or exogenous glucagon-like peptide 1 (GLP-1) do not alter plasma leptin concentrations in healthy volunteers.
    Drewes C, Nauck MA, Horn R, Holst J, Schmiegel W, Brabant G.
    Acta Diabetol; 1997 Oct; 34(3):230-4. PubMed ID: 9401646
    [Abstract] [Full Text] [Related]

  • 2. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
    Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH.
    Am J Physiol; 1997 Nov; 273(5):E981-8. PubMed ID: 9374685
    [Abstract] [Full Text] [Related]

  • 3. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.
    Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA.
    J Clin Endocrinol Metab; 1996 Jan; 81(1):327-32. PubMed ID: 8550773
    [Abstract] [Full Text] [Related]

  • 4. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.
    Vilsbøll T, Krarup T, Madsbad S, Holst JJ.
    Regul Pept; 2003 Jul 15; 114(2-3):115-21. PubMed ID: 12832099
    [Abstract] [Full Text] [Related]

  • 5. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects.
    Meier JJ, Kemmeries G, Holst JJ, Nauck MA.
    Diabetes; 2005 Jul 15; 54(7):2212-8. PubMed ID: 15983224
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
    Vilsbøll T, Toft-Nielsen MB, Krarup T, Madsbad S, Dinesen B, Holst JJ.
    Diabetes Care; 2000 Jun 15; 23(6):807-12. PubMed ID: 10841001
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Glucagon-like peptide 1 increases mass but not frequency or orderliness of pulsatile insulin secretion.
    Pørksen N, Grøfte B, Nyholm B, Holst JJ, Pincus SM, Veldhuis JD, Schmitz O, Butler PC.
    Diabetes; 1998 Jan 15; 47(1):45-9. PubMed ID: 9421373
    [Abstract] [Full Text] [Related]

  • 10. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.
    Nauck MA, Wollschläger D, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Willms B.
    Diabetologia; 1996 Dec 15; 39(12):1546-53. PubMed ID: 8960841
    [Abstract] [Full Text] [Related]

  • 11. Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM.
    Dupre J, Behme MT, Hramiak IM, McFarlane P, Williamson MP, Zabel P, McDonald TJ.
    Diabetes; 1995 Jun 15; 44(6):626-30. PubMed ID: 7789625
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM.
    Gutniak MK, Linde B, Holst JJ, Efendić S.
    Diabetes Care; 1994 Sep 15; 17(9):1039-44. PubMed ID: 7988303
    [Abstract] [Full Text] [Related]

  • 16. The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones.
    Toft-Nielson M, Madsbad S, Holst JJ.
    Diabetes; 1996 May 15; 45(5):552-6. PubMed ID: 8621002
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance.
    Ritzel R, Schulte M, Pørksen N, Nauck MS, Holst JJ, Juhl C, März W, Schmitz O, Schmiegel WH, Nauck MA.
    Diabetes; 2001 Apr 15; 50(4):776-84. PubMed ID: 11289042
    [Abstract] [Full Text] [Related]

  • 19. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.
    Quddusi S, Vahl TP, Hanson K, Prigeon RL, D'Alessio DA.
    Diabetes Care; 2003 Mar 15; 26(3):791-8. PubMed ID: 12610039
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.